Dynavax Technologies Corporation (NASDAQ:DVAX) Short Interest Update

Dynavax Technologies Corporation (NASDAQ:DVAX) saw a large decline in short interest during the month of January. As of January 15th, there was short interest totaling 9,129,174 shares, a decline of 14.0% from the December 31st total of 10,619,836 shares. Based on an average daily volume of 4,971,230 shares, the days-to-cover ratio is presently 1.8 days. Currently, 8.0% of the company’s stock are sold short. Currently, 8.0% of the company’s stock are sold short. Based on an average daily volume of 4,971,230 shares, the days-to-cover ratio is presently 1.8 days.

Insider Activity

In other news, COO David F. Novack sold 114,000 shares of the stock in a transaction that occurred on Thursday, January 15th. The stock was sold at an average price of $15.64, for a total transaction of $1,782,960.00. Following the completion of the transaction, the chief operating officer directly owned 63,344 shares in the company, valued at approximately $990,700.16. This represents a 64.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 2.98% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Dynavax Technologies

Several large investors have recently added to or reduced their stakes in the stock. Danske Bank A S acquired a new position in shares of Dynavax Technologies during the fourth quarter valued at $34,000. Hantz Financial Services Inc. boosted its stake in Dynavax Technologies by 236.9% during the 3rd quarter. Hantz Financial Services Inc. now owns 3,854 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 2,710 shares during the period. Mirae Asset Global Investments Co. Ltd. boosted its stake in Dynavax Technologies by 25.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,706 shares of the biopharmaceutical company’s stock valued at $88,000 after purchasing an additional 1,172 shares during the period. LSV Asset Management bought a new position in Dynavax Technologies in the 3rd quarter worth about $89,000. Finally, Osaic Holdings Inc. increased its stake in shares of Dynavax Technologies by 15.1% in the second quarter. Osaic Holdings Inc. now owns 9,336 shares of the biopharmaceutical company’s stock valued at $93,000 after purchasing an additional 1,226 shares during the period. 96.96% of the stock is owned by institutional investors and hedge funds.

Dynavax Technologies Stock Up 0.2%

DVAX stock opened at $15.51 on Thursday. The firm has a market cap of $1.82 billion, a price-to-earnings ratio of -41.92 and a beta of 0.97. Dynavax Technologies has a 1-year low of $9.20 and a 1-year high of $15.73. The firm has a fifty day moving average price of $13.77 and a two-hundred day moving average price of $11.60. The company has a debt-to-equity ratio of 0.41, a current ratio of 7.62 and a quick ratio of 6.94.

Dynavax Technologies (NASDAQ:DVAX) last posted its quarterly earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.21 EPS for the quarter, beating the consensus estimate of $0.14 by $0.07. The business had revenue of $94.88 million during the quarter, compared to analyst estimates of $94.00 million. Dynavax Technologies had a negative net margin of 13.13% and a positive return on equity of 7.18%. Research analysts predict that Dynavax Technologies will post 0.32 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Weiss Ratings reiterated a “sell (d)” rating on shares of Dynavax Technologies in a research note on Wednesday, January 21st. William Blair lowered shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research note on Wednesday, December 24th. Finally, Wall Street Zen raised shares of Dynavax Technologies from a “buy” rating to a “strong-buy” rating in a research report on Saturday, December 27th. Two investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Dynavax Technologies currently has an average rating of “Hold” and an average target price of $24.33.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.